Harith Rajagopalan, Fractyl Health CEO

Fractyl pitch­es po­ten­tial of GLP-1 gene ther­a­py, but push­es clin­i­cal tri­als back to 2025

A small biotech com­pa­ny is de­vel­op­ing a one-time gene ther­a­py that could turn the pan­creas in­to its own GLP-1 drug fac­to­ry and elim­i­nate the need …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.